natgillin/translations-raw huggingface dataset:
An antibody for the use according to any of claims 16 to 22 wherein the antibody designated herein as CAN34D03-65 is administered subcutaneously at 1.0 mg/kg, wherein CAN34D03-65 is represented by SEQ ID NO:31 (VH) paired with SEQ ID NO: 25 (VL) on SEQ ID NO:42 (HC-65) and SEQ ID NO: 44 (LC-Kappa). 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 16 do 22, naznačeno time što se protutijelo označeno ovdje kao CAN34D03-65 primjenjuje supkutano u dozi od 1,0 mg/kg, gdje CAN34D03-65 je predstavljeno s SEQ ID NO:31 (VH) u paru s SEQ ID NO: 25 (VL) na SEQ ID NO: 42 (HC-65) i SEQ ID NO: 44 (LC-k).
n represents an integer of 0, 1, 2, 3, 4 or 5; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same. 
n predstavlja cijeli broj od 0, 1, 2, 3, 4 ili 5; ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, ili smjesa istih.
R' and R" represent, independently from each other, a substituent selected from: 
R' i R" predstavljaju, međusobno neovisno, supstituent odabran od:
n represents an integer of 0 or 1; 
n predstavlja cijeli broj od 0 ili 1;
The compound according to claim 1, which is trans-3-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}cyclobutanamine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je trans-3-{[3-(1-benzofuran-2-il)imidazo[1,2-b]piridazin-6-il]oksi}ciklobutanamin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
The compound according to claim 1, which is 3-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}-3-methylbutan-1-amine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je 3-{[3-(1-benzofuran-2-il)imidazo[1,2-b]piridazin-6-il]oksi}-3-metilbutan-1-amin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
The compound according to claim 1, which is 2-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}-4-methylpentan-1-amine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je 2-{[3-(1-benzofuran-2-il)imidazo[1,2-b]piridazin-6-il]oksi}-4-metilpentan-1-amin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
The compound according to claim 1, which is 3-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}-2-methylpropan-1-amine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je 3-{[3-(1-benzofuran-2-il)imidazo[1,2-b]piridazin-6-il]oksi}-2-metilpropan-1-amin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
A pharmaceutical combination comprising: 
Farmaceutski kombinacija naznačena time da sadrži:
A compound for use according to claim 20, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the MKNK-1 pathway, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or metastases thereof, e.g . 
Spoj za uporabu prema zahtjevu 20, naznačen time da navedena bolest je bolest nekontroliranog staničnog rasta, proliferacije i/ili preživljavanja, neodgovarajućeg staničnog imunog odgovora, ili neprimjerenog staničnog upalnog odgovora, naročito u kojem su nekontrolirani rast stanica, proliferacija i/ili preživljavanje, neodgovarajući stanični imuni odgovor ili neodgovarajući stanični upalni odgovor posredovani pomoću MKNK-1 puta, osobito u kojem bolest nekontroliranog rasta stanica, proliferacija i/ili preživljavanje, neodgovarajući stanični imuni odgovor ili neodgovarajući stanični upalni odgovor je hematološki tumor, njegov solidni tumor i/ili metastaze, npr.
11 A compound according to any one of claims 1 to 11 for use in a method of treating a disease or disorder selected from pain, drug addiction, opiate addiction, alcohol addiction, nicotine addiction, cocaine addiction, post-operative ileus, pruritis, diarrhea, irritable bowel syndrome, gastrointestinal motility disorder, obesity, respiratory depression, convulsions, coughing, and hyperalgesia. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 11 za upotrebu u postupku za liječenje bolesti ili poremećaja izabranog od boli, ovisnosti o lijekovima, ovisnosti o opijatima, ovisnosti o alkoholu, ovisnosti o nikotinu, ovisnosti o kokainu, post-operativnog ileusa, pruritisa, dijareje, sindroma iritabilnog crijeva, poremećaja gastrointestinalne pokretljivosti, pretilosti, respiratorne depresije, konvulzija, kašlja i hiperalgezije.
A compound for use according to claim 12 wherein said disease or disorder is pain. 
Spoj za upotrebu prema patentnom zahtjevu 12 naznačeno time što navedena bolest ili poremećaj je bol.
A compound for use according to claim 12 wherein said disease or disorder is selected from drug addiction, opiate addiction, alcohol addiction, nicotine addiction, cocaine addiction, post-operative ileus, pruritis, diarrhea, irritable bowel syndrome, gastrointestinal motility disorder, obesity, respiratory depression, convulsions, coughing, hyperalgesia. 
Spoj za upotrebu prema patentnom zahtjevu 12 naznačeno time što je navedena bolest ili poremećaj izabran od ovisnosti o lijekovima, ovisnosti o opijatima, ovisnosti o alkoholu, ovisnosti o nikotinu, ovisnosti o kokainu, post-operativnog ileusa, pruritisa, dijareje, sindroma iritabilnog crijeva, poremećaja gastrointestinalne pokretljivosti, pretilosti, respiratorne depresije, konvulzija, kašlja, hiperalgezije.
A compound for use in a method of treating or preventing a side effect associated with an opioid, said method comprising the step of: administering to a patient in need thereof, a composition comprising an effective amount of a compound according to any of claims 1-11. 
Spoj za upotrebu u postupku za liječenje ili prevenciju sporednog efekta povezanog s opioidom, pri čemu navedeni postupak sadrži korak: primjene na pacijenta kod kojeg postoji potreba za tim, kompozicije koja sadrži efikasnu količinu spojeva prema bilo kojem od patentnih zahtjeva 1-11.
A compound for use according to claim 20, wherein the side effect is selected from the group consisting of constipation, opioid-induced bowel dysfunction, nausea, vomiting, and combinations thereof. 
Spoj za upotrebu prema patentnom zahtjevu 20, naznačeno time što je sporedni efekt izabran iz grupe koja se sastoji od konstipacije, disfunkcije crijeva inducirane opioidom, mučnine, povraćanja i njihovih kombinacija.
Acamprosate, or a salt thereof, or a sustained-release formulation thereof, for use in combination with baclofen, or a salt thereof, or a sustained-release formulation thereof, in a method of treatment of ALS or a related disorder selected from Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Pseudobulbar Palsy and Progressive Bulbar Palsy (PBP) and Fronto Temporal Dementia (FTD). 
Akamprosat, ili njegova sol, ili njegova formulacija s produženim otpuštanjem, za uporabu u kombinaciji s baklofenom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, u postupku za liječenje ALS ili srodnog poremećaja koji se bira od primarne lateralne skleroze (PLS), progresivne mišićne atrofije (PMA), pseudobulbarne paralize i progresivne bulbarne paralize (PBP) i frontalno-temporalne demencije (FTD).
Acamprosate, or a salt thereof, or a sustained-release formulation thereof, for use in combination with baclofen or a salt thereof, or a sustained-release formulation thereof, and riluzole, or a salt thereof, or a sustained-release formulation thereof, in a method of treatment of ALS or a related disorder selected from Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Pseudobulbar Palsy and Progressive Bulbar Palsy (PBP) and Fronto Temporal Dementia (FTD). 
Akamprosat, ili njegova sol, ili njegova formulacija s produženim otpuštanjem, za uporabu u kombinaciji s baklofenom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, te riluzolom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, u postupku za liječenje ALS ili srodnog poremećaja koji se bira od primarne lateralne skleroze (PLS), progresivne mišićne atrofije (PMA), pseudobulbarne paralize i progresivne bulbarne paralize (PBP) i frontalno-temporalne demencije (FTD).
A composition comprising an extract of adlay bran, wherein the extract of adlay bran comprises a C1 to C7 alcohol extract of adlay bran (A) and a carbon dioxide supercritical fluid extract of adlay bran (B), and the weight ratio of the C1 to C7 alcohol extract of adlay bran (A) to the carbon dioxide supercritical fluid extract of adlay bran (B) is from about 3:1 to about 1:4. 
Pripravak comprising an ekstrakt mekinja Jobovih suza, naznačen time što ekstrakt mekinja Jobovih suza sadrži C1 do C7 alkoholni ekstrakt mekinja Jobovih suza (A) i ekstrakt mekinja Jobovih suza suprakritičnim ugljičnom dioksidom (B), gdje se težinski omjer između C1 do C7 alkoholnog ekstrakta mekinja Jobovih suza (A) i ekstrakta mekinja Jobovih suza suprakritičnim ugljičnom dioksidom (B) kreće od otprilike 3:1 do otprilike 1:4.
The composition for use according to claim 8, wherein the skin and/or subcutaneous tissue disease is selected from the group consisting of inflammation, hair follicle damage, skin atrophy, bruising, burn, cheilitis, dry skin, flushing, alopecia, hyperpigmentation, hypopigmentation, induration, fibrosis, injection site reaction, extravasation change, nail change, photosensitivity, pruritus, itching, rash, desquamation, acne, acneiform, dermatitis associated with radiation, erythema multiforme, hand-foot skin reaction, skin breakdown, decubitus ulcer, striae, telangiectasia, ulceration, and urticaria. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se bolest kože i/ili potkožnog tkiva bira iz skupine koju čine upala, oštećenje folikula kose, atrofija kože, masnice, opekline, heilitis, suha koža, rumenilo, alopecija, hiperpigmentacija, hipopigmentacija, otvrdnuće, fibroza, reakcija na mjestu injekcije, ekstravazacijska promjena, promjena na noktima, fotoosjetljivost, pruritus, svrbež, osip, deskvamacija, akne, akneiformne pojave, dermatitis povezan sa zračenjem, poliformni eritem, kožna reakcija noga-ruka, propadanje kože, dekubitalni ulkus, strije, telangiektazija, ulceracija i koprivnjača.
The composition for use to claim 8 or 9, wherein the skin and/or subcutaneous tissue disease is caused by radiation. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8 ili 9, naznačen time što je bolest kože i/ili potkožnog tkiva uzrokovana zračenjem.
an active ingredient consisting of a compound according to claim 1 or 2 or a polymorphic form according to claim 3, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži: aktivni sastojak koji se sastoji od spoja prema zahtjevu 1 ili 2 ili polimorfnog oblika prema zahtjevu 3, te farmaceutski prihvatljiv nosač.
The pharmaceutical composition according to claim 5 or 6, wherein the pharmaceutical composition is formulated for topical administration in a form selected from a lotion, a cream, a gel, an oil, an ointment, a salve, an emulsion, a solution, and a suspension. 
Farmaceutski pripravak prema zahtjevu 5 ili 6, naznačen time da je farmaceutski pripravak formuliran za topikalnu primjenu u obliku odabranom od losiona, kreme, gela, ulja, masti, melema, emulzije, otopine, te suspenzije.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 10, wherein the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, a complication from localized or total-body exposure to ionizing radiation, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 10, naznačen time da stanje je kožna bolest ili poremećaj, sepsa, dermatitis, osteoartritis, rak, upala, autoimuna bolest, upalna bolest crijeva, komplikacija od lokaliziranog ili cjelokupnog izlaganja ionizirajućem zračenju, mukozitis, akutno ili kronično zatajenje organa, bolest jetre, pankreatitis, poremećaj oka, plućna bolest, ili dijabetes.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is a skin disease or disorder selected from dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, other disorders of the hair follicle, epidermolysis bullosa, sunburn, complications of sunburn, a disorder of skin pigmentation, an aging-related skin condition, a post-surgical wound, a scar from a skin injury or burn, psoriasis, a dermatological manifestation of an autoimmune disease or a graft-versus host disease, skin cancer, and a disorder involving hyperproliferation of skin cells. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je kožna bolest ili poremećaj koji se bira od dermatitisa, toplinskih ili kemijskih opeklina, kronične rane, akni, alopecije, drugih poremećaja folikula kose, bulozne epidermolize, opeklina od sunca, komplikacija opeklina od sunca, poremećaja pigmentacije kože, stanja kože povezanog sa starenjem, rana nakon operacije, ožiljka od ozljede kože ili opeklina, psorijaze, dermatološke manifestacija autoimune bolesti ili bolesti presatka protiv domaćina, raka kože, te poremećaja koji obuhvaćaju hiperproliferaciju stanica kože.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is dermatitis, which is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je dermatitis, koji je alergijski dermatitis, atopijski dermatitis, dermatitis zbog izloženosti kemikalijama, ili dermatitis izazvan zračenjem.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is an autoimmune disease selected from rheumatoid arthritis, lupus, Crohn's disease, and psoriasis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je autoimuna bolest odabrana od reumatoidnog artritisa, lupusa, Crohnove bolesti, te psorijaze.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is a liver disease selected from fatty liver disease and hepatitis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je bolest jetre odabrana od bolesti masne jetre i hepatitisa.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is an eye disorder selected from uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis, and a form of conjunctivitis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je poremećaj oka odabran od uveitisa, makularne degeneracije, glaukoma, dijabetičkog makularnog edema, blefaritisa, dijabetičke retinopatije, bolesti ili poremećaja endotela rožnice, postoperativna upala, sindrom suhog oka, alergijski konjunktivitis, te oblik konjunktivitis.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is a lung disease selected from pulmonary inflammation, pulmonary fibrosis, COPD, asthma, cystic fibrosis, and idiopathic pulmonary fibrosis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je plućna bolest odabrana od upale pluća, plućne fibroze, KOPB, astme, cistične fibroze, te idiopatske plućne fibroze.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is cancer and the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je rak, i rak je rak mjehura, krvi, kostiju, mozga, dojke, središnjeg živčanog sustava, grlića maternice, debelog crijeva, endometrija, jednjaka, žučnog mjehura, genitalija, genitourinarnog trakta, glave, bubrega, grkljana, jetre, pluća, mišićnog tkiva, vrata, oralne ili nosne sluznice, jajnika, gušterače, prostate, kože, slezene, tankog crijeva, debelog crijeva, želuca, testisa ili štitnjače.
The compound, the polymorphic form, or the pharmaceutical composition for use according to any one of claims 10 to 22, wherein the compound, the polymorphic form, or the pharmaceutical composition is administered both before and after the subject is treated with radiation therapy or chemotherapy. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 10 do 22, naznačen time da se spoj, polimorfni oblik, ili farmaceutski pripravak primjenjuje i prije i poslije nakon što je subjekt liječen zračenjem ili kemoterapijom.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 23, wherein the treatment reduces a side effect of the radiation therapy or the chemotherapy. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 23, naznačen time da liječenje smanjuje nuspojavu terapije zračenjem ili kemoterapijom.
Where Ab is an antibody that binds to HER2, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1; and wherein the drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to about 8. 
[image] gdje Ab predstavlja protutijelo koje se veže na HER2, pri čemu protutijelo obuhvaća VH-domenu koja ima sekvencu u skladu sa SEQ ID NO:1; i pri čemu popunjenje supstancom (p) od lijekova (D) spram protutijela (Ab), iznosi cijeli broj od 1 do oko 8.
The conjugate according to claim 1 comprising a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5. 
Konjugat prema zahtjevu 1, naznačen time, da obuhvaća konjugirane spojeve protutijelo-lijek, pri čemu prosječno popunjenje supstancom po protutijelu, u mješavini konjugiranih spojeva protutijelo-lijek, iznosi od oko 2 do oko 5.
The conjugate according to claim 11, wherein the cancer is selected from the group consisting of: breast cancer, gastric cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, endometrial cancer, head and neck cancer and salivary gland carcinoma. 
Konjugat prema zahtjevu 11, naznačen time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak dojke, rak želudca, rak mjehura, rak gušterače, kolorektalni rak, rak cerviksa, rak jajnika, rak prostate, rak ne-malih stanica pluća, endometrijski rak, rak glave i vrata te karcinom žlijezde slinovnice.
A pharmaceutical composition comprising the conjugate of any one of claims 1 to 8 and a pharmaceutically acceptable diluent, carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća konjugat prema bilo kojem od zahtjeva 1 do 8, te farmaceutski prihvatljiv razrjeđivač, nosač ili pomoćno sredstvo.
The pharmaceutical composition of claim 13 further comprising a therapeutically effective amount of a chemotherapeutic agent. 
Farmaceutski sastav prema zahtjevu 13, naznačen time, da dodatno obuhvaća terapeutski učinkovitu količinu kemoterapeutskog sredstva.
The crystal according to claim 2, having endothermic peak top temperatures in differential scanning calorimeter analysis of 229 to 232 degree C, and 300 to 303 degree C. 
Kristal sukladno patentnom zahtjevu 2, koji najviše temperature endotermičkog vrha u analizi diferencijalne skenirajuće kalorimetrije od 229 do 232 stupnjeva C, i 300 do 303 stupnjeva C.
The pharmaceutical composition according to claim 4, which is a pharmaceutical composition for preventing or treating thrombocytopenia. 
Farmaceutska tvar sukladno patentnom zahtjevu 4, koja je farmaceutska tvar radi sprječavanja ili liječenja trombocitopenije.
A method of making micelles comprising rabies virus (RV) glycoproteins (G proteins), wherein the G proteins form a trimer comprising: 
Postupak za izradu micela, koje sadrđe glikoproteine (G proteine) virusa bjesnoće (RV), naznačen time da G proteini tvore trimer koji sadrži:
purifying the RV G protein in the form of micelles. 
Pročišćavanje G proteina od virusa bjesnila (RV) u obliku micela.
The method of claim 1, wherein the nucleic acid is codon optimised for expression in said host cells. 
Postupak sukladno patentnom zahtjevu 1, naznačen time da je nukleinska kiselina kodon optimizirana za ekspresiju u navedenim stanicama domaćina.
The method of claim 1 or claim 2, wherein the RV G protein comprises SEQ ID NO:2. 
Postupak sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time da G protein od virusa bjesnoće (RV) sadrži SEK ID BR:2.
A method of making a vaccine or antigenic composition, comprising making micelles comprising rabies virus glycoproteins by the method according to any one of claims 1 to 4, and further comprising a step of formulating the micelles as a vaccine or antigenic composition by adding an effective dose of the micelles to the composition. 
Postupak za pripravu cjepiva ili antigenskog pripravka, koji obuhvaća izradu micela, koje sadrže glikoproteine iz virusa bjesnoće, pomoću postupka metodom prema bilo kojem od patentnih zahtjeva 1 do 4 te nadalje obuhvata korak formuliranja micela kao cjepiva ili antigenskog sastava, dodavanjem djelotvorne doze od micela do sastava.
The method of claim 9, wherein the micelles are capable of inducing the production of anti-G protein antibodies in the host after administration of a single dose. 
Postupak sukladno patentnom zahtjevu 9, naznačen time da su micele sposobne inducirati proizvodnju antitela protiv G proteina u domaćinu, nakon davanja jedne doze.
The method of claim 9, wherein the micelles are capable of providing a seroprotective titer in 7 days. 
Postupak sukladno patentnom zahtjevu 9, naznačen time da su micele podobne osigurati seroprotektivni titar unutar 7 dan
The shipping container (1) of Claim 1 or 2 wherein the base unit (10) is a rectangular base unit (10). 
Transportni spremnik (1) sukladno patentnom zahtjevu 1 ili 2 pri čemu je osnovna jedinica (10) pravokutna osnovna jedinica (10).
amino acid sequences that have no more than 3, preferably no more than 2, more preferably no more than 1 amino acid difference with one of SEQ ID NO's: 138-141 and 154-157, provided that: 
sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 60-76, pod uvjetom da: